Trial reportInternal and emergency medicine2014
Lactobacillus reuteri in the treatment of Helicobacter pylori infection.
Trial report in Internal and emergency medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy of prebiotics and probiotics for functional dyspepsia: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Probiotic monotherapy andWorld journal of gastroenterology · 2018Pooled it
- Pooled it
- Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial.Clinical and translational gastroenterology · 2024Trial
- Trial
- Trial
- High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.Asian Pacific journal of cancer prevention : APJCP · 2019Trial
- Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study.Probiotics and antimicrobial proteins · 2015Trial
- Effects of Lactobacillus spp. on Helicobacter pylori: A Promising Frontier in the Era of Antibiotic Resistance.Probiotics and antimicrobial proteins · 2025Review
- Gastric microbiome-derived Lacticaseibacillus casei strain RIGLD MG-1 relieves Helicobacter pylori-induced inflammation in gastric epithelial cells in vitro.Molecular biology reports · 2025Article
- Delivery of Probiotic-Loaded Microcapsules in the Gastrointestinal Tract: A Review.Probiotics and antimicrobial proteins · 2025Review
- Study on the alleviative effect ofInfection and immunity · 2024Article
- Unraveling the Puzzle: Health Benefits of Probiotics-A Comprehensive Review.Journal of clinical medicine · 2024Review
- Enhancement of host defense againstFrontiers in immunology · 2024Article
- Probiotics and autoprobiotics for treatment ofWorld journal of clinical cases · 2023Review
- Integrative ATAC-seq and RNA-seq analyses of IPEC-J2 cells reveals porcine transcription and chromatin accessibility changes associated withFrontiers in microbiology · 2023Article
- Article
- The impacts of probiotics in eradication therapy of Helicobacter pylori.Archives of microbiology · 2022Review
- Review
- Antibacterial Effects of Bacteriocin PLNC8 againstFoods (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics have proven to be useful in the treatment of a number of gastrointestinal diseases. Probiotics may compete directly with Helicobacter pylori, possibly by interference with adherence or by the production of antimicrobial molecules. Lactobacillus reuteri has been shown to inhibit H. pylori in vitro and in vivo, and theoretically may play a role in eradication therapy. The aim of this study was to examine the efficacy of L. reuteri in H. pylori eradication therapy. This was an open label single center study. H. pylori infection was defined as positive gastric histopathology and (13)C-UBT. Intervention consisted of L. reuteri (DSM 17938) 10(8) cfu plus pantoprazole 20 mg twice a day for 8 weeks. Eradication was defined as a negative (13)C-UBT, 4-6 weeks post therapy. Compliance was considered good if at least 90% of the total number of the pills were taken. 21 of 22 subjects completed the study without protocol violation (mean age 52 years; 36% men). L. reuteri plus pantoprazole twice a day cured 13.6% (3/22; 95% CI 2.9-34.9%) of patients with H. pylori infection by ITT analysis and 14.2% (3/21; 95% CI 3.0-36%) by PP analysis. Overall urease activity assessed before and 4-6 weeks post therapy showed a significant reduction with a difference of mean of 38.8 vs. 25.4 by one-tailed test (P = 0.002). In conclusion, L. reuteri may have a potential role in H. pylori eradication therapy if the cure rate can be improved by changes in dose, dosing interval, or duration of therapy.
Indexed as
Identifiers
24178436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.